News | December 10, 2023
Pfizer presents marstacimab Phase 3 Data at ASH 2023
Demonstrate significant bleed reduction in hemophilia A and B
Demonstrate significant bleed reduction in hemophilia A and B
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Approval to dramatically change CAR-T therapies landscape
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Subscribe To Our Newsletter & Stay Updated
